Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15075053 | 0.86 | ALDH1A1 (0.62) | ANPEPALDH1A1GAAHDAC4HDAC7 | |
| SCHEMBL6045078 | 0.83 | ANPEP (0.53) | ANPEPALDH1A1GAAHDAC4HDAC7 | |
| SCHEMBL11764934 | 0.80 | ANPEP (0.50) | ANPEPALDH1A1GAAHDAC4HDAC7 | |
| Cyheptamide SCHEMBL667894 | 0.79 | ALDH1A1 (0.62) | ALDH1A1GAAHDAC4HDAC7HDAC5 | |
| Cyheptamide SCHEMBL29400142 | 0.79 | ALDH1A1 (0.62) | ALDH1A1GAAHDAC4HDAC7HDAC5 | |
| SCHEMBL1207850 | 0.77 | HDAC4 (0.51) | ANPEPHDAC4HDAC7HDAC5HTR2A | |
| SCHEMBL1998760 | 0.74 | HDAC4 (0.44) | ANPEPALDH1A1GAAHDAC4HDAC7 | |
| SCHEMBL30873765 | 0.73 | ANPEP (0.60) | ANPEPGAAHTR2ALMNAHRH1 | |
| SCHEMBL4959541 | 0.73 | ANPEP (0.60) | ANPEPGAAHTR2ALMNAHRH1 | |
| SCHEMBL6514594 | 0.72 | ANPEP (0.59) | ANPEPHDAC4HDAC7HDAC5HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | ANPEP 2278/4885ALDH1A1 2036/4885GAA 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.